The whole-PTH/intact-PTH ratio is a useful predictor of severity of secondary hyperparathyroidism

NDT Plus

Volumn 1, Issue SUPPL.3, 2008, Pages

  Tanaka, Motoko ^a   Komaba, Hirotaka ^b   Itoh, Kazuko ^a   Matsushita, Kazunori ^a   Matshushita, Kazutaka ^a   Hamada, Yasuhiro ^b   Fujii, Hideki ^b   Fukagawa, Masafumi ^b  

^a Akebono Clinic   (Japan)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

1 84 PTH; Haemodialysis; New molecular form of PTH; Secondary hyperparathyroidism; Whole PTH intact PTH ratio

Indexed keywords

PARATHYROID HORMONE;

AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NODULAR HYPERPLASIA; PARATHYROID GLAND; PARATHYROID HYPERPLASIA; PARATHYROIDECTOMY; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM;

EID: 48749121547     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfn089     Document Type: Article

References (23)

1. Malluche HH, Faugere MC. Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int 1990; 38: 193-211
2. Parfitt AM. Parathyroid growth: normal and abnormal. In: Bilezikian JP, Marcus R, Levine MA (eds). The Parathyroid: Basic & Clinical Concepts. New York: Raven Press, 1994, 373
3. Tominaga Y, Grimelius L, Falkmer UG et al. DNA ploidy pattern of parathyroid parenchymal cells in renal secondary hyperparathyroidism with relapse. Anal Cell Pathol 1991; 3: 325-333
4. Tominaga Y, Tanaka Y, Sato K et al. Recurrent renal hyperparathyroidism and DNA analysis of autografted parathyroid tissue. World Surg 1992; 16: 595-603
5. Tominaga Y, Tanaka Y, Sato K et al. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997; 13: 78-86
6. Arnold A, Brown MF, Urena P et al. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995; 95: 2047-2053
7. Fukuda N, Tanaka H, Tominaga Y et al. Decreased 1,25-dihydroxyvitamin D3 receptor density associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92: 1436-1443
8. 2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81: 1598-1606
9. Gogusev J, Duchambon P, Hory B et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997; 51: 328-336
10. Fukagawa M, Kitaoka M, Inazawa T et al. Imaging of the parathyroid in chronic renal failure: diagnostic and therapeutic aspects. Curr Opin Nephrol Hypertens 1997; 6: 349-355
11. Fukagawa M, Tominaga Y, Kitaoka M et al. Medical and surgical aspects of parathyroidectomy. Kidney Int 1999; 73: S65-S69
12. Blind E, Schmidt-Gayk H, Scharla S et al. Two-site assay of intact parathyroid hormone in the investigation of primary hyperparathyroidism and other disorders of calcium metabolism compared with a midregion assay. J Clin Endocrinol Metab 1988; 67: 353-360
13. Goodman WG. New assays for parathyroid hormone (PTH) and the relevance of PTH fragments in renal failure. Kidney Int 2003; 87: S120-S124
14. Yamashita H, Gao P, Cantor T et al. Comparison of parathyroid hormone levels from the intact and whole parathyroid hormone assays after parathyroidectomy for primary and secondary hyperparathyroidism. Surgery 2004; 135: 149-156
15. Nakanishi S, Kazama JJ, Shigematsu T et al. Comparison of intact PTH assay and whole PTH assay in long-term dialysis patients. Am J Kidney Dis 2001; 38(Suppl 1): S172-S174
16. Inaba M, Nakatsuka K, Imanishi Y et al. Technical and clinical characterization of the Bio-PTH (1-84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone. Clin Chem 2004; 50: 385-390
17. Rubin MR, D'Amour P, Brossard JH et al. A molecular form of PTH distinct from PTH (1-84) is produced in parathyroid carcinoma. J Bone Mineral Res 2004; 19(Suppl 1): S327
18. D'Amour P, Brossard JH, Rousseau L et al. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1-84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem 2003; 49: 2037-2044
19. Tanaka M, Itoh K, Matsushita K et al. Normalization of reversed biointact-PTH(1-84)/intact-PTH ratio after parathyroidectomy in a patient with severe secondary hyperparathyroidism. Clin Nephrol 2005; 64: 69-72
20. Arakawa T, D'Amour P, Rousseau L et al. Overproduction and secretion of a novel amino-terminal form of PTH from a severe type of parathyroid hyperplasia in uremia. Clin J Am Soc Nephrol 2006; 1: 525-531
21. Fukagawa M, Hamada Y, Nakanishi S et al. The kidney and bone metabolism: nephrologists' point of view. J Bone Miner Metab 2006; 24: 434-438
22. Monier-Faugere MC, Geng Z, Mawad H et al. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 2001; 60: 1460-1468
23. Kazama JJ, Omori K, Higuchi N et al. Intact PTH assay overestimates true 1-84 PTH levels after maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2004; 19: 892-897